https://orcid.org/0000-0001-9209-2405
Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ibrahim Malami, Aisha Muktar Bunza, Alhassan Muhammad Alhassan, Aliyu Muhammad, Ibrahim Babangida Abubakar, Abdulmajeed Yunusa, Peter M. Waziri & Imaobong C. Etti. (2022) Dihydroartemisinin as a potential drug candidate for cancer therapy: a structural-based virtual screening for multitarget profiling. Journal of Biomolecular Structure and Dynamics 40:3, pages 1347-1362.
Read now
Read now
Articles from other publishers (10)
Jubie Selvaraj, Motamarri Venkata Naga Lalitha Chaitanya, Akey Krishna Swaroop, Prabha Thangavelu & Rashmi Saxena Pal. 2023. Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach. Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach
122
138
.
Boryana Nikolova-Mladenova, Georgi Momekov, Zvetanka Zhivkova & Irini Doytchinova. (2023) Design, Synthesis and Cytotoxic Activity of Novel Salicylaldehyde Hydrazones against Leukemia and Breast Cancer. International Journal of Molecular Sciences 24:8, pages 7352.
Crossref
Crossref
Indira Singaram, Ashutosh Sharma, Shashank Pant, Muyun Lihan, Mi-Jeong Park, Melissa Pergande, Pawanthi Buwaneka, Yusi Hu, Nadim Mahmud, You-Me Kim, Stephanie Cologna, Vladimir Gevorgyan, Irum Khan, Emad Tajkhorshid & Wonhwa Cho. (2022) Targeting lipid–protein interaction to treat Syk-mediated acute myeloid leukemia. Nature Chemical Biology 19:2, pages 239-250.
Crossref
Crossref
Mandy Beyer, Sven J. Henninger, Patricia S. Haehnel, Al-Hassan M. Mustafa, Ece Gurdal, Bastian Schubert, Markus Christmann, Andreas Sellmer, Siavosh Mahboobi, Sebastian Drube, Wolfgang Sippl, Thomas Kindler & Oliver H. Krämer. (2022) Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. Cell Chemical Biology 29:3, pages 398-411.e4.
Crossref
Crossref
Hany S. Ibrahim, Mohamed Abdelsalam, Yanira Zeyn, Matthes Zessin, Al-Hassan M. Mustafa, Marten A. Fischer, Patrik Zeyen, Ping Sun, Emre F. Bülbül, Anita Vecchio, Frank Erdmann, Matthias Schmidt, Dina Robaa, Cyril Barinka, Christophe Romier, Mike Schutkowski, Oliver H. Krämer & Wolfgang Sippl. (2021) Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity. International Journal of Molecular Sciences 23:1, pages 369.
Crossref
Crossref
Devipriya Padmakumar, Vineetha Radhakrishnan Chandraprabha, Preethi Gopinath, Akhila Raj Thampirajan Vimala Devi, Geetha Raj John Anitha, Mahitha Mohanan Sreelatha, Amritha Padmakumar & Hariharan Sreedharan. (2021) A concise review on the molecular genetics of acute myeloid leukemia. Leukemia Research 111, pages 106727.
Crossref
Crossref
Jenna L. Carter, Katie Hege, Jay Yang, Hasini A. Kalpage, Yongwei Su, Holly Edwards, Maik Hüttemann, Jeffrey W. Taub & Yubin Ge. (2020) Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Nikola Skoupa, Petr Dolezel & Petr Mlejnek. (2020) Lysosomal Fusion: An Efficient Mechanism Increasing Their Sequestration Capacity for Weak Base Drugs without Apparent Lysosomal Biogenesis. Biomolecules 10:1, pages 77.
Crossref
Crossref
Xin Hua, Yue Sun, Jing Chen, Ying Wu, Jun Sha, Shuhua Han & Xiaoli Zhu. (2019) Circular RNAs in drug resistant tumors. Biomedicine & Pharmacotherapy 118, pages 109233.
Crossref
Crossref
Neha AmatyaDavid Yin-wei LinAmy H. Andreotti. (2019) Dynamic regulatory features of the protein tyrosine kinases. Biochemical Society Transactions 47:4, pages 1101-1116.
Crossref
Crossref